Sarah Ford | February 9, 2015
Research progress report: Frizzled 9 and lung cancer chemoprevention
Every year, lung cancer leads to more deaths than any other cancer. An estimated 159,2601Â Americans were expected to die from lung cancer in 2014, accounting for about 27% of all cancer deaths.
The Foundation is committed to lung cancer prevention research and currently supports five researchers studying different aspects of preventing this deadly disease. One of these researchers is Meredith Tennis, Ph.D., of the University of Colorado Denver. Her project focuses on Frizzled 9, a protein that helps to maintain normal lung tissue, as a potential biomarker2Â to predict how patients may respond to the drug iloprost, a drug being used for chemoprevention.
Get Resources and Insights Straight To Your Inbox
Explore More Articles
Congratulations to Our Members Recognized Among America’s Favorite Charities
Each year, The Chronicle of Philanthropy releases its list of America’s Favorite Charities—the 100 nonprofits that raise the most from individual donors, foundations, and corporate…
Read Article
The Future of Corporate Giving: How Nonprofits Can Prepare
Corporate giving is a valuable part of the nonprofit funding ecosystem. Companies large and small have incorporated philanthropic efforts into their overall business plans, from…
Read Article
Join Us at the Workplace Fundraising & Volunteering Summit!
We’re excited to announce that America’s Charities President, Jim Starr, and Board Member, Fernando Lorence of JP Morgan Chase, will be speaking at the Workplace…
Read ArticleGet Resources and Insights Straight To Your Inbox
Receive our monthly/bi-monthly newsletter filled with information about causes, nonprofit impact, and topics important for corporate social responsibility and employee engagement professionals, including disaster response, workplace giving, matching gifts, employee assistance funds, volunteering, scholarship award program management, grantmaking, and other philanthropic initiatives.
